Reference health
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
27/27 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
The 27 checked references that resolve
resolves10.1111/his.12307
Loss of membranous expression of the intracellular domain of Ep<scp>CAM</scp> is a frequent event and predicts poor survival in patients with pancreatic cancer
resolves10.1016/S0140-6736(00)03312-2
Ep-CAM overexpression in breast cancer as a predictor of survival
resolves10.1002/ijc.10270
Prognostic significance of Ep‐CAM AND Her‐2/neu overexpression in invasive breast cancer
resolves10.1016/j.ygyno.2006.03.035
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer
resolves10.1016/j.yexcr.2005.06.013
The cell–cell adhesion molecule EpCAM interacts directly with the tight junction protein claudin-7
resolves10.1158/1541-7786.MCR-08-0200
Claudin-7 Regulates EpCAM-Mediated Functions in Tumor Progression
resolves10.1016/S1040-8428(01)00131-7
Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma
resolves10.1159/000318055
Phase II Study of the Human Anti-Epithelial Cell Adhesion Molecule Antibody Adecatumumab in Prostate Cancer Patients with Increasing Serum Levels of Prostate-Specific Antigen after Radical Prostatectomy
resolves10.1093/annonc/mdp314
An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer
resolves10.1126/science.1158545
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
resolves10.1016/S1470-2045(14)71170-2
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
resolves10.1182/blood-2015-06-651380
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
resolves10.1016/j.molimm.2005.03.007
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells
resolves10.1158/0008-5472.CAN-04-2637
Eradication of Tumors from a Human Colon Cancer Cell Line and from Ovarian Cancer Metastases in Immunodeficient Mice by a Single-Chain Ep-CAM-/CD3-Bispecific Antibody Construct
resolves10.1016/j.clcc.2016.07.009
Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas
resolves10.1200/JCO.2014.56.3247
Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
resolves10.1007/s00262-008-0529-y
Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans
resolves10.1007/s00280-015-2728-5
A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3
resolves10.1016/j.molimm.2005.07.034
MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
resolves10.1182/blood-2012-01-400515
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab
resolves10.1158/0008-5472.CAN-07-2182
Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3
resolves10.1158/1078-0432.CCR-04-0729
ING-1, a Monoclonal Antibody Targeting Ep-CAM in Patients with Advanced Adenocarcinomas
resolves10.1093/annonc/mdm280
Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineered™ monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1080/2162402x.2018.1450710"><img src="https://citestamp.com/citestamped/10.1080/2162402x.2018.1450710/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1080/2162402x.2018.1450710)